Robert A. Burger

22.7k total citations · 9 hit papers
202 papers, 14.8k citations indexed

About

Robert A. Burger is a scholar working on Reproductive Medicine, Surgery and Obstetrics and Gynecology. According to data from OpenAlex, Robert A. Burger has authored 202 papers receiving a total of 14.8k indexed citations (citations by other indexed papers that have themselves been cited), including 137 papers in Reproductive Medicine, 53 papers in Surgery and 52 papers in Obstetrics and Gynecology. Recurrent topics in Robert A. Burger's work include Ovarian cancer diagnosis and treatment (133 papers), Endometrial and Cervical Cancer Treatments (50 papers) and Intraperitoneal and Appendiceal Malignancies (39 papers). Robert A. Burger is often cited by papers focused on Ovarian cancer diagnosis and treatment (133 papers), Endometrial and Cervical Cancer Treatments (50 papers) and Intraperitoneal and Appendiceal Malignancies (39 papers). Robert A. Burger collaborates with scholars based in United States, Germany and Japan. Robert A. Burger's co-authors include Bradley J. Monk, Benjamin E. Greer, Helen Huang, Rebecca N. Baergen, Brian N. Bundy, Jeffrey M. Fowler, Robert S. Mannel, Mark F. Brady, Deborah K. Armstrong and Joan L. Walker and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Robert A. Burger

196 papers receiving 14.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer

2006 1.9k citations Deborah K. Armstrong, Brian N. Bundy et al. profile →
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

2011 1.6k citations Robert A. Burger, Mark F. Brady et al. profile →
Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study

2003 1.6k citations Robert F. Ozols, Brian N. Bundy et al. Journal of Clinical Oncology profile →
Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study

2007 647 citations Robert A. Burger, Michael W. Sill et al. Journal of Clinical Oncology profile →
Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer

2007 574 citations Ursula A. Matulonis, Richard T. Penson et al. Journal of Clinical Oncology profile →
Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer

2001 546 citations Bradley J. Monk, Robert A. Burger et al. profile →
Inherited Mutations in Women With Ovarian Carcinoma

2015 503 citations Mark F. Brady, Robert A. Burger et al. profile →
Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup

2009 500 citations Michael A. Bookman, Mark F. Brady et al. Journal of Clinical Oncology profile →
Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study

2020 224 citations Dmitriy Zamarin, Robert A. Burger et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Robert A. Burger

Since Specialization

Citations

This map shows the geographic impact of Robert A. Burger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert A. Burger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert A. Burger more than expected).

Fields of papers citing papers by Robert A. Burger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert A. Burger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert A. Burger. The network helps show where Robert A. Burger may publish in the future.

Co-authorship network of co-authors of Robert A. Burger

This figure shows the co-authorship network connecting the top 25 collaborators of Robert A. Burger. A scholar is included among the top collaborators of Robert A. Burger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert A. Burger. Robert A. Burger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	2022-RA-439-ESGO Up-next (ENGOT-Ov71-NSGO-CTU/GOG-3049): a study of upitifamab rilsodotin (UpRi), a napi2b-directed antibody drug conjugate (ADC) in platinum-sensitive recurrent ovarian cancer 2022 ·International Journal of Gynecological Cancer ·Mansoor Raza Mirza, David M. O’Malley, Philipp Harter, Thomas J. Herzog, Antonio González-Martı́n, (unknown), Robert A. Burger, Debra L. Richardson	1
2	32 UPGRADE: phase 1 combination trial of the NaPi2b-directed antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi; XMT-1536) in patients with ovarian cancer 2022 ·Gynecologic Oncology Reports ·Theresa L. Werner, Nehal J. Lakhani, William J. Edenfield, John L. Hays, Corrine Zarwan, Joseph Buscema, Timothy F. Burns, (unknown), Erika Krasnickas Keeton, Robert A. Burger, Charles Anderson	1
3	Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study breakdown → 2020 ·Journal of Clinical Oncology ·Dmitriy Zamarin, Robert A. Burger, Michael W. Sill, Daniel J. Powell, Heather A. Lankes, Michael D. Feldman, Oliver Zivanovic, Camille C. Gunderson, Emily Ko, Cara Mathews, Sudarshan Sharma, Andrea R. Hagemann, Samir N. Khleif, Carol Aghajanian	224
4	Ovarian granulosa cell tumor characterization identifies FOXL2 as an immunotherapeutic target 2020 ·JCI Insight ·Stefano Pierini, János L. Tanyi, Fiona Simpkins, Erin George, Mireia Uribe‐Herranz, Ronny Drapkin, Robert A. Burger, Mark A. Morgan, Andrea Facciabene	19
5	HIF Inactivation of p53 in Ovarian Cancer Can Be Reversed by Topotecan, Restoring Cisplatin and Paclitaxel Sensitivity 2019 ·Molecular Cancer Research ·(unknown), Robert A. Burger, (unknown), John P. Fruehauf	32
6	Exceptional Response to Nivolumab in a 13-Year-Old Female with Metastatic HPV-Negative Cervical Carcinoma 2019 ·DNA and Cell Biology ·Joseph H. Oved, (unknown), Robert A. Burger, Lauren E. Schwartz, María C. Reyes, Frank M. Balis	0
7	Systemic Treatment of Metastatic/Recurrent Uterine Leiomyosarcoma: A Changing Paradigm 2018 ·The Oncologist ·Rebecca C. Arend, (unknown), (unknown), Robert A. Burger, Alexander Olawaiye, Bradley J. Monk, Thomas J. Herzog	19
8	An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience 2017 ·Gynecologic Oncology ·Kate Oliver, William E. Brady, Michael J. Birrer, David M. Gershenson, Gini F. Fleming, Larry J. Copeland, Krishnansu S. Tewari, Peter A. Argenta, Robert S. Mannel, Angeles Alvarez Secord, (unknown), David G. Mutch, Frederick B. Stehman, Franco M. Muggia, Peter G. Rose, Deborah K. Armstrong, Michael A. Bookman, Robert A. Burger, John Farley	62
9	Incidence of Venous Thromboembolism by Type of Gynecologic Malignancy and Surgical Modality in the National Surgical Quality Improvement Program 2017 ·International Journal of Gynecological Cancer ·(unknown), Nawar Latif, Xiaochen Zhang, Lorraine T. Dean, Mark A. Morgan, Robert Giuntoli, Robert A. Burger, Sarah Kim, Emily Ko	46
10	Use of CA-125 Tests and Computed Tomographic Scans for Surveillance in Ovarian Cancer 2016 ·Obstetrical & Gynecological Survey ·Katharine M. Esselen, Angel M. Cronin, Kristin Bixel, Michael A. Bookman, Robert A. Burger, David E. Cohn, Mihaela Cristea, Jennifer J. Griggs, Charles F. Levenback, Gina Mantia-Smaldone, Larissa A. Meyer, Ursula A. Matulonis, Joyce C. Niland, Charlotte C. Sun, David M. O’Malley, Alexi A. Wright	13
11	Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer 2015 ·Obstetrical & Gynecological Survey ·Alexi A. Wright, Angel M. Cronin, Dana Milne, Michael A. Bookman, Robert A. Burger, David E. Cohn, Mihaela Cristea, Jennifer J. Griggs, Nancy L. Keating, Charles F. Levenback, Gina Mantia-Smaldone, Ursula A. Matulonis, Larissa A. Meyer, Joyce C. Niland, Jane C. Weeks, David M. O’Malley	5
12	American Society of Clinical Oncology Position Statement on Obesity and Cancer 2015 ·Obstetrical & Gynecological Survey ·Jennifer A. Ligibel, Catherine M. Alfano, Kerry S. Courneya, Wendy Demark‐Wahnefried, Robert A. Burger, Rowan T. Chlebowski, Carol J. Fabian, Ayca Gucalp, Dawn L. Hershman, Melissa M. Hudson, Lee W. Jones, Madhuri Kakarala, Kirsten K. Ness, Janette K. Merrill, Dana S. Wollins, Clifford A. Hudis	7
13	Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study 2015 ·Annals of Oncology ·Krishnansu S. Tewari, James Java, Ramez N. Eskander, Bradley J. Monk, Robert A. Burger	91
14	PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer 2013 ·Journal of Clinical Oncology ·R. Wendel Naumann, Robert L. Coleman, Robert A. Burger, Edward A. Sausville, E. Kutarska, Sharad Ghamande, Nashat Gabrail, Stephen DePasquale, Elżbieta Nowara, Lucy Gilbert, Robert H. Gersh, Michael Teneriello, Wael A. Harb, Panagiotis A. Konstantinopoulos, Richard T. Penson, James T. Symanowski, (unknown), Christopher P. Leamon, David Morgenstern, Richard A. Messmann	169
15	Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer 2012 ·Obstetrical & Gynecological Survey ·Robert A. Burger, Mark F. Brady, Michael A. Bookman, Gini F. Fleming, Bradley J. Monk, Helen Huang, Robert S. Mannel, Howard D. Homesley, Jeffrey M. Fowler, Benjamin E. Greer, Matthew Boente, Michael J. Birrer, Sharon X. Liang	197
16	Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup breakdown → 2009 ·Journal of Clinical Oncology ·Michael A. Bookman, Mark F. Brady, William P. McGuire, Peter Harper, David S. Alberts, Michael Friedländer, Nicoletta Colombo, Jeffrey M. Fowler, Peter A. Argenta, Koen De Geest, David G. Mutch, Robert A. Burger, Ann Marie Swart, Edward L. Trimble, (unknown), Lawrence M. Roth	500
17	Angiogenesis in gynecological oncology-mechanism of tumor progression and therapeutic targets 2005 ·International Journal of Gynecological Cancer ·Kanwaldeep Kaur Rasila, Robert A. Burger, Harriet O. Smith, (unknown), Claire F. Verschraegen	50
18	Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study breakdown → 2003 ·Journal of Clinical Oncology ·Robert F. Ozols, Brian N. Bundy, Benjamin E. Greer, Jeffrey M. Fowler, Daniel L. Clarke‐Pearson, Robert A. Burger, Robert S. Mannel, Koen DeGeest, Ellen M. Hartenbach, Rebecca N. Baergen	1591
19	Phase II Trial of Navelbine in Advanced Epithelial Ovarian Cancer 1997 ·Gynecologic Oncology ·Robert A. Burger, P.J. DiSaia	4
20	Hamartoma of the hypothalamus 1953 ·The Journal of Pediatrics ·Peter Marcuse, Robert A. Burger, (unknown)	31

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact